Pharmafile Logo
Pharmafocus logo
Advanced Search
dna

Companies face mixed fortunes in ultra-orphan approvals

November 26, 2015
Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs

UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …

Feature
gsk_boronia_australia

GSK begins Phase III study of sirukumab in giant cell arteritis

November 26, 2015
Business Services, Research and Development, Sales and Marketing GSK, Janssen

GSK today announced it has begun a Phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the …

News
shire_image_4

Shire prepares new Baxalta bid

November 26, 2015
Business Services, Sales and Marketing

Following rejection in an earlier bid, it has emerged that Shire is preparing a new takeover offer for US biotech …

News
Chest x ray

Lilly cancer drug gets US approval

November 26, 2015
NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

News
trump_and_clinton

Trump and Clinton hit out at Pfizer over tax inversion plan

November 25, 2015
Sales and Marketing Allergan, Pfizer

Politicians on both sides of the US spectrum have criticised Pfizer over its $160 billion buyout of Allergan and its …

News
10_downing_street

UK Spending Review: science budget protected, NHS gets £10 billion boost

November 25, 2015
Research and Development

Feared 40% cuts to the UK’s science budget failed to materialise today, as Chancellor George Osborne announced the budget would …

News
Takeda oncology

Challenges in oncology R&D – part 2

November 25, 2015
Manufacturing and Production, Research and Development R&D, Takeda, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Feature
Medicines Patent Pool

BMS and Medicines Patent Pool collaborate to increase Hep C medicine access

November 25, 2015
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C

The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …

News
Teva image

Teva and Heptares enter $400m agreement for small-molecule migraine treatment

November 25, 2015
Research and Development Heptares, Teva, collaboration, migraine

Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …

News
Dementia scan

UK commits £150 million to new Dementia Research Institute

November 25, 2015
Research and Development dementia. R&D

The UK government has launched plans for a new £150 million dementia research institute that it says will drive a …

News
BMS

Bristol-Myers Squibb in new oncology collaboration

November 25, 2015
Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital

Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies.  The companies …

News
nick_plaquetec_c-4

PlaqueTec appoints Dr Nick West as CMO

November 24, 2015
Research and Development PlaqueTec

PlaqueTec has appointed Dr Nick West as its new chief medical officer.  Dr West is a research-active clinician with extensive …

Appointment
opdivo

FDA approves BMS’s Opdivo for renal cell carcinoma

November 24, 2015
Research and Development

The FDA has approved Bristol Myers Squibb’s immunotherapy Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC). …

News
Arzerra

Genmab pulls plug on Phase III Arzerra trial

November 24, 2015
Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …

News
Catapult cell therapy

Construction for new £55m cell and gene manufacturing centre in Stevenage begins

November 24, 2015
Manufacturing and Production Catapult, Cell Therapy Catapult, Hertfordshire, gene therapy, manufacturing, stevenage

The Government-backed Cell Therapy Catapult has begun the construction for its cell and gene therapy manufacturing centre.   The construction …

News
Beximco logo

FDA approves Beximco to manufacture Carvedilol for US

November 24, 2015
Manufacturing and Production Bangladesh, Beximco, Carvediol, FDA, exports, generics

Beximco Pharmaceuticals has become the first Bangladeshi pharma company to receive approval for a prescription drug to be manufactured in …

News
EU flag

Novartis and Amgen drugs signed-off by European Commission

November 24, 2015
Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto

The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …

News
NN Tianjin plant

Novo Nordisk to go green by 2020

November 24, 2015
Manufacturing and Production Novo Nordish, manufacturing, production, renewable energy

Novo Nordisk has announced plans to go green in the next five years by using only electricity from renewable sources …

News

OmniaMed UK appoints new senior management

November 24, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

OmniaMed has strengthened its senior management team by appointing Dr Clive Deverson as managing director and Dr Colin Griffin as …

Appointment
merck-sharp--dohme-corp

MSD launches new antibiotic in the UK

November 23, 2015
Manufacturing and Production, Research and Development

Merck (MSD) has launched the new intravenous antibiotic Zerbaxa (ceftolozane/tazobactam) in the UK, for the treatment of complicated intra-abdominal infections …

News
The Gateway to Local Adoption Series

Latest content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026

BioDuro and CTI Biotechnology in preclinical drug development partnership

May 21, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

May 21, 2026

NICE recommends sotatercept for pulmonary arterial hypertension

May 20, 2026

Vetter begins construction of new injectable medicines facility

May 20, 2026